

# **Asia Pacific Biosimilars Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Disease Indication (Cancer, Diabetes, Autoimmune Diseases, and Other Diseases), Drug Class (Granulocyte Colony-Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers & Monoclonal Antibodies, Erythropoietin-Stimulating Agents, and Others), Route of Administration (Intravenous, Subcutaneous, and Others), and End User (Hospitals, Speciality Clinics, Homecare, and Others)**

<https://marketpublishers.com/r/A357FFDA145CEN.html>

Date: April 2023

Pages: 176

Price: US\$ 3,000.00 (Single User License)

ID: A357FFDA145CEN

## **Abstracts**

The Asia Pacific biosimilars market is expected to grow from US\$ 3,141.28 million in 2022 to US\$ 22,533.11 million by 2028. It is estimated to grow at a CAGR of 38.9% from 2022 to 2028.

### **Patent Expiry of Blockbuster Biologics is Driving Asia Pacific Biosimilars Market**

Biologicals represent promising new therapies for previously incurable diseases and are becoming highly important in the pharmaceuticals market. Patents on originator biologicals are expected to expire in the coming years. The patent expiration and other intellectual property rights for originator biologicals will create a need to introduce new biosimilars in the future. As a result, competition among market players will surge in the industry in the coming years. Thus, the patent expiry of blockbuster biologics is expected to create lucrative opportunities for the biosimilar market during the forecast period.

## Asia Pacific Biosimilars Market Overview

According to Generics and Biosimilars Initiative (GaBI), in 2021, the National Medical Products Administration (NMPA) has approved 13 copy biologicals, within the product classes of monoclonal antibody and tumour necrosis factor (TNF)-inhibitor, for use in China.

In February 2019, China's first official biosimilar was approved. The rituximab biosimilar HLX01 was developed by Shanghai Henlius Biopharmaceutical for the treatment of Non-Hodgkin's Lymphoma (NHL). Three more biosimilars were approved in China in 2019, and seven biosimilars were approved in 2020, at an increase of 75% between 2019 and 2020. A bevacizumab biosimilar by Luye Pharma Group Ltd was approved in May 2021 for non-small cell lung cancer, and an infliximab biosimilar by Mabpharm Ltd was approved in July 2021 for ankylosing spondylitis.

Thus, the Chinese biosimilars will continue to surge in the future, with 11 biosimilars in pre-registration awaiting NMPA approval and approximately 100 biosimilars in development. Therefore, China's strong biosimilar pipeline and the NMPA's latest regulation changes will foster growth in China's biosimilar market.

## Asia Pacific Biosimilars Market Revenue and Forecast to 2028 (US\$ Million)

### Asia Pacific Biosimilars Market Segmentation

The Asia Pacific biosimilars market is segmented into disease indication, drug class, route of administration, end user, and country.

Based on disease indication, the biosimilars market is segmented into cancer, diabetes, autoimmune diseases, and other disease indications. The cancer segment held the largest market share in 2022.

The biosimilars market, based on drug class, is segmented into granulocyte colony-stimulating stimulating factors, human growth hormone, insulin, TNF blockers & monoclonal antibodies, erythropoietin-stimulating stimulating agents, and others. The granulocyte colony-stimulating factors segment accounted for the largest share of the market in 2022.

Based on route of administration, the biosimilar market is segmented into intravenous,

subcutaneous, and others. The intravenous segment accounted for the largest share of the market in 2022.

The biosimilars market, based on end user, is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment accounted for the largest share of the market in 2022.

Based on country, the Asia Pacific biosimilars market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the market in 2022.

Amgen Inc; Sanofi SA; Biocon Ltd; Eli Lilly and Co; Sandoz AG; Teva Pharmaceutical Industries Ltd; Pfizer Inc; and Dr. Reddy's Laboratories Ltd; Celltrion Inc; Samsung Bioepis Co Ltd are the leading companies operating in the Asia Pacific biosimilars market.

## Contents

### **1. INTRODUCTION**

- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
  - 1.3.1 Asia Pacific Biosimilars Market – by Disease Indication
  - 1.3.2 Asia Pacific Biosimilars Market – by Drug class
  - 1.3.3 Asia Pacific Biosimilars Market – by Route of Administration
  - 1.3.4 Asia Pacific Biosimilars Market – by End User
  - 1.3.5 Asia Pacific Biosimilars Market – by Country

### **2. ASIA PACIFIC BIOSIMILARS MARKET – KEY TAKEAWAYS**

### **3. RESEARCH METHODOLOGY**

- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research

### **4. ASIA PACIFIC BIOSIMILARS MARKET – MARKET LANDSCAPE**

- 4.1 Overview
- 4.2 Asia Pacific PEST Analysis
- 4.3 Expert's Opinion

### **5. ASIA PACIFIC BIOSIMILARS MARKET – KEY MARKET DYNAMICS**

- 5.1 Market Drivers
  - 5.1.1 Increasing Prevalence of Chronic Diseases
  - 5.1.2 Cost Effectiveness of Biosimilar Drugs
  - 5.1.3 Rising Approvals of Biosimilars
- 5.2 Market Restraints
  - 5.2.1 High-Cost Involvement and Complexities in Biosimilar Product Manufacturing
- 5.3 Market Opportunities
  - 5.3.1 Patent Expiry of Blockbuster Biologics
- 5.4 Future Trend

- 5.4.1 Collaborations for Biosimilars and Clinical Trials
- 5.5 Impact analysis

## **6. BIOSIMILARS MARKET – ASIA PACIFIC ANALYSIS**

- 6.1 Asia Pacific Biosimilars Market Revenue Forecast and Analysis

## **7. ASIA PACIFIC BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – BY DISEASE INDICATION**

- 7.1 Overview
- 7.2 Asia Pacific Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)
- 7.3 Cancer
  - 7.3.1 Overview
  - 7.3.2 Cancer: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
- 7.4 Diabetes
  - 7.4.1 Overview
  - 7.4.2 Diabetes: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
- 7.5 Autoimmune Diseases
  - 7.5.1 Overview
  - 7.5.2 Autoimmune Diseases: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
  - 7.5.3 Psoriasis:
    - 7.5.3.1 Overview
    - 7.5.3.2 Psoriasis: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
  - 7.5.4 Arthritis:
    - 7.5.4.1 Overview
    - 7.5.4.2 Arthritis: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
  - 7.5.5 Others:
    - 7.5.5.1 Overview
    - 7.5.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
- 7.6 Others Disease Indications
  - 7.6.1 Overview
  - 7.6.2 Others Disease Indications: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

## **8. ASIA PACIFIC BIOSIMILARS MARKET ANALYSIS AND FORECAST TO 2028 – BY DRUG CLASS**

## 8.1 Overview

### 8.2 Asia Pacific Biosimilars Market, by Drug class 2021 & 2028 (%)

## 8.3 Granulocyte colony-stimulating factors

### 8.3.1 Overview

#### 8.3.2 Granulocyte colony-stimulating factors Drug class: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

## 8.4 Insulin

### 8.4.1 Overview

#### 8.4.2 Insulin Drug class: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

## 8.5 TNF Blockers and Monoclonal Antibodies

### 8.5.1 Overview

#### 8.5.2 TNF Blockers and Monoclonal Antibodies Drug class: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

## 8.6 Others

### 8.6.1 Overview

#### 8.6.2 Others Drug class: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

## **9. ASIA PACIFIC BIOSIMILARS MARKET ANALYSIS AND FORECASTS TO 2028 – BY ROUTE OF ADMINISTRATION**

## 9.1 Overview

### 9.2 Asia Pacific Biosimilars Market, by Application 2021 & 2028 (%)

## 9.3 Intravenous

### 9.3.1 Overview

#### 9.3.2 Intravenous: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

## 9.4 Subcutaneous

### 9.4.1 Overview

#### 9.4.2 Subcutaneous: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

## 9.5 Others

### 9.5.1 Overview

#### 9.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

## **10. ASIA PACIFIC BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – BY END USER**

## 10.1 Overview

10.2 Asia Pacific Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)

10.3 Hospitals

10.3.1 Overview

10.3.2 Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

10.4 Specialty Clinics

10.4.1 Overview

10.4.2 Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

10.5 Homecare

10.5.1 Overview

10.5.2 Homecare: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

10.6 Other

10.6.1 Overview

10.6.2 Other: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

## **11. ASIA PACIFIC BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – COUNTRY ANALYSIS**

11.1 Overview

11.1.1.1 China: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

11.1.1.1.1 Overview

11.1.1.1.2 China: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

11.1.1.1.3 China: Biosimilars Market, by Disease Indication, 2019–2028 (US\$ Million)

11.1.1.1.3.1 China: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US\$ Million)

11.1.1.1.4 China: Biosimilars Market, by Drug Class, 2019–2028 (US\$ Million)

11.1.1.1.5 China: Biosimilars Market, by Route of Administration, 2019–2028 (US\$ Million)

11.1.1.1.6 China Biosimilars Market, by End User, 2019–2028 (US\$ Million)

11.1.1.2 Japan: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

11.1.1.2.1 Overview

11.1.1.2.2 Japan: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

11.1.1.2.3 Japan: Biosimilars Market, by Disease Indication, 2019–2028 (US\$ Million)

11.1.1.2.3.1 Japan: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US\$ Million)

11.1.1.2.4 Japan: Biosimilars Market, by Drug Class, 2019–2028 (US\$ Million)

11.1.1.2.5 Japan: Biosimilars Market, by Route of Administration, 2019–2028 (US\$ Million)

11.1.1.2.6 Japan: Biosimilars Market, by End User, 2019–2028 (US\$ Million)

- 11.1.1.3 India: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
  - 11.1.1.3.1 Overview
  - 11.1.1.3.2 India: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
  - 11.1.1.3.3 India: Biosimilars Market, by Disease Indication, 2019–2028 (US\$ Million)
    - 11.1.1.3.3.1 India: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US\$ Million)
    - 11.1.1.3.4 India: Biosimilars Market, by Drug Class, 2019–2028 (US\$ Million)
    - 11.1.1.3.5 India: Biosimilars Market, by Route of Administration, 2019–2028 (US\$ Million)
    - 11.1.1.3.6 India: Biosimilars Market, by End User, 2019–2028 (US\$ Million)
- 11.1.1.4 South Korea: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
  - 11.1.1.4.1 Overview
  - 11.1.1.4.2 South Korea: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
  - 11.1.1.4.3 South Korea: Biosimilars Market, by Disease Indication, 2019–2028 (US\$ Million)
    - 11.1.1.4.3.1 South Korea: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US\$ Million)
    - 11.1.1.4.4 South Korea: Biosimilars Market, by Drug Class, 2019–2028 (US\$ Million)
    - 11.1.1.4.5 South Korea: Biosimilars Market, by Route of Administration, 2019–2028 (US\$ Million)
    - 11.1.1.4.6 South Korea: Biosimilars Market, by End User, 2019–2028 (US\$ Million)
- 11.1.1.5 Australia: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
  - 11.1.1.5.1 Overview
  - 11.1.1.5.2 Australia: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
  - 11.1.1.5.3 Australia: Biosimilars Market, by Disease Indication, 2019–2028 (US\$ Million)
    - 11.1.1.5.3.1 Australia: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US\$ Million)
    - 11.1.1.5.4 Australia: Biosimilars Market, by Drug Class, 2019–2028 (US\$ Million)
    - 11.1.1.5.5 Australia: Biosimilars Market, by Route of Administration, 2019–2028 (US\$ Million)
    - 11.1.1.5.6 Australia: Biosimilars Market, by End User, 2019–2028 (US\$ Million)
- 11.1.1.6 Rest of Asia Pacific: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
  - 11.1.1.6.1 Overview
  - 11.1.1.6.2 Rest of Asia Pacific: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
  - 11.1.1.6.3 Rest of Asia Pacific: Biosimilars Market, by Disease Indication, 2019–2028 (US\$ Million)



11.1.1.6.3.1 Rest of Asia Pacific: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US\$ Million)

11.1.1.6.4 Rest of Asia Pacific: Biosimilars Market, by Drug Class, 2019–2028 (US\$ Million)

11.1.1.6.5 Rest of Asia Pacific: Biosimilars Market, by Route of Administration, 2019–2028 (US\$ Million)

11.1.1.6.6 Rest of Asia Pacific: Biosimilars Market, by End User, 2019–2028 (US\$ Million)

## **12. BIOSIMILARS MARKET – INDUSTRY LANDSCAPE**

12.1 Overview

12.2 Growth Strategies in the Biosimilars Market

12.3 Inorganic Growth Strategies

12.3.1 Overview

12.4 Organic Growth Strategies

12.4.1 Overview

## **13. COMPANY PROFILES**

13.1 Amgen Inc

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Celltrion Inc

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Sanofi SA

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
- 13.4 Biocon Ltd
  - 13.4.1 Key Facts
  - 13.4.2 Business Description
  - 13.4.3 Products and Services
  - 13.4.4 Financial Overview
  - 13.4.5 SWOT Analysis
  - 13.4.6 Key Developments
- 13.5 Samsung Bioepis Co Ltd
  - 13.5.1 Key Facts
  - 13.5.2 Business Description
  - 13.5.3 Products and Services
  - 13.5.4 Financial Overview
  - 13.5.5 SWOT Analysis
  - 13.5.6 Key Developments
- 13.6 Eli Lilly and Co
  - 13.6.1 Key Facts
  - 13.6.2 Business Description
  - 13.6.3 Products and Services
  - 13.6.4 Financial Overview
  - 13.6.5 SWOT Analysis
  - 13.6.6 Key Developments
- 13.7 Sandoz AG
  - 13.7.1 Key Facts
  - 13.7.2 Business Description
  - 13.7.3 Products and Services
  - 13.7.4 Financial Overview
  - 13.7.5 SWOT Analysis
  - 13.7.6 Key Developments
- 13.8 Teva Pharmaceutical Industries Ltd
  - 13.8.1 Key Facts
  - 13.8.2 Business Description
  - 13.8.3 Products and Services
  - 13.8.4 Financial Overview
  - 13.8.5 SWOT Analysis
  - 13.8.6 Key Developments
- 13.9 Pfizer Inc
  - 13.9.1 Key Facts

- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
- 13.10 Dr. Reddy's Laboratories Ltd
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

## **14. APPENDIX**

- 14.1 About The Insight Partners
- 14.2 Glossary of Terms

## List Of Tables

### LIST OF TABLES

Table 1. Comparison Between Different Drug Developments

Table 2. China Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US\$ Million)

Table 3. China Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US\$ Million)

Table 4. China Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US\$ Million)

Table 5. China Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US\$ Million)

Table 6. China Biosimilars Market, by End User – Revenue and Forecast to 2028 (US\$ Million)

Table 7. Japan Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US\$ Million)

Table 8. Japan Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US\$ Million)

Table 9. Japan Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US\$ Million)

Table 10. Japan Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US\$ Million)

Table 11. Japan Biosimilars Market, by End User – Revenue and Forecast to 2028 (US\$ Million)

Table 12. India Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US\$ Million)

Table 13. India Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US\$ Million)

Table 14. India Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US\$ Million)

Table 15. India Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US\$ Million)

Table 16. India Biosimilars Market, by End User – Revenue and Forecast to 2028 (US\$ Million)

Table 17. South Korea Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US\$ Million)

Table 18. South Korea Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US\$ Million)

Table 19. South Korea Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US\$ Million)

Table 20. South Korea Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US\$ Million)

Table 21. South Korea Biosimilars Market, by End User – Revenue and Forecast to 2028 (US\$ Million)

Table 22. Australia Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US\$ Million)

Table 23. Australia Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US\$ Million)

Table 24. Australia Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US\$ Million)

Table 25. Australia Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US\$ Million)

Table 26. Australia Biosimilars Market, by End User – Revenue and Forecast to 2028 (US\$ Million)

Table 27. Rest of Asia Pacific Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US\$ Million)

Table 28. Rest of Asia Pacific Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US\$ Million)

Table 29. Rest of Asia Pacific Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US\$ Million)

Table 30. Rest of Asia Pacific Biosimilars Market, by Route of Administration – Revenue and Forecast to 2028 (US\$ Million)

Table 31. Rest of Asia Pacific Biosimilars Market, by End User – Revenue and Forecast to 2028 (US\$ Million)

Table 32. Recent Inorganic Growth Strategies in the Biosimilars Market

Table 33. Recent Organic Growth Strategies in the Biosimilars Market

Table 34. Glossary of Terms

## List Of Figures

### LIST OF FIGURES

- Figure 1. Asia Pacific Biosimilars Market Segmentation
- Figure 2. Asia Pacific Biosimilars Market, by Country
- Figure 3. Asia Pacific Biosimilars Market Overview
- Figure 4. Cancer Segment Held Largest Share of Type Segment in Asia Pacific Biosimilars Market
- Figure 5. India is Expected to Show Remarkable Growth During Forecast Period
- Figure 6. Asia Pacific: PEST Analysis
- Figure 7. Experts' Opinion
- Figure 8. Asia Pacific Biosimilars Market Impact Analysis of Drivers and Restraints
- Figure 9. Asia Pacific Biosimilars Market – Revenue Forecast and Analysis – 2020–2028
- Figure 10. Asia Pacific Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)
- Figure 11. Cancer: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 12. Diabetes: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 13. Autoimmune Diseases: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 14. Psoriasis: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 15. Arthritis: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 16. Others: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 17. Others Disease Indications: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 18. Asia Pacific Biosimilars Market, by Drug class 2021 & 2028 (%)
- Figure 19. Granulocyte colony-stimulating factors Drug class: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 20. Insulin Drug class: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 21. TNF Blockers and Monoclonal Antibodies Drug class: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 22. Others Drug class: Asia Pacific Biosimilars Market – Revenue and Forecast

to 2028 (US\$ Million)

Figure 23. Asia Pacific Biosimilars Market, by Application 2021 & 2028 (%)

Figure 24. Intravenous: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 25. Subcutaneous: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 26. Others: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 27. Asia Pacific Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)

Figure 28. Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 29. Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 30. Homecare: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 31. Other: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 32. Asia Pacific: Biosimilars Market, by Key Country – Revenue (2021) (US\$ Million)

Figure 33. Asia Pacific: Biosimilars Market, by Country, 2021 & 2028 (%)

Figure 34. China: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 35. Japan: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 36. India: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 37. South Korea: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 38. Australia: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 39. Rest of Asia Pacific: Biosimilars Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 40. Growth Strategies in the Biosimilars Market

## I would like to order

Product name: Asia Pacific Biosimilars Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Disease Indication (Cancer, Diabetes, Autoimmune Diseases, and Other Diseases), Drug Class (Granulocyte Colony-Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers & Monoclonal Antibodies, Erythropoietin-Stimulating Agents, and Others), Route of Administration (Intravenous, Subcutaneous, and Others), and End User (Hospitals, Speciality Clinics, Homecare, and Others)

Product link: <https://marketpublishers.com/r/A357FFDA145CEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A357FFDA145CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms



& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970